In a study published in the Journal of the National Cancer Institute, Mass General Brigham researchers show that a novel ...

RAIPUR: The annual Chhattisgarh Cancer Conclave held at the Balco Medical Centre (BMC) in Nava Raipur featured live surgical ...

The committee recommended Keytruda's subcutaneous form for all indications and as neoadjuvant/adjuvant treatment in PD-L1-positive head and neck cancer.

Nanobiotix S.A. stock surges on promising cancer trial results and major partnership. Click for more on NBTX stock and why ...

First combination therapy to report 29.5 months of Median Overall Survival (mOS); Standard of care Keytruda® (pembrolizumab) alone (10.8 months) and Keytruda® + chemotherapy (12.3 months) in patients ...

The FDA has granted fast track designation to the antibody-drug conjugate (ADC) CRB-701 for the treatment of recurrent or ...

Heidi Berghäll, EQA Solutions Manager, R&D of Labquality, commented, "It is important that both pathology and molecular tests are validated via a proper EQA scheme to monitor ongoing performance.

Half-Year Results and Business UpdatePositive Phase I data with TG4050 in operable Head and Neck Squamous Cell Carcinoma (HNSCC) 100% ...

Human papilloma virus (HPV) causes around 70% of head and neck cancers in the United States, making it the most common cancer caused by the virus, with rates increasing each year.

DeepSeek, developed by Mass General Brigham researchers, offers early detection of HPV-associated head and neck cancers, ...

Human papillomavirus (HPV) causes around 70% of head and neck cancers in the United States, making it the most common cancer ...

Researchers hope the advanced warning could enable earlier, less invasive treatments with fewer side effects and better outcomes.